DPI Research Academy

It is predicted that Zika virus vaccines shot will available to the public by 2018. Zika virus is an emerging viral disease that is transmitted through the bite of an infected mosquito, primarily Aedes aegypti, the same vector that transmits chikungunya, dengue and yellow fever. Zika has a similar epidemiology, clinical presentation and transmission cycle in urban environments as chikungunya and dengue, although it generally causes milder illness.  The highest risk is to pregnant women due to the connection the virus has with serious birth defects.  Pregnant women who contract the virus have a high possibility of giving birth to a baby with microcephaly, a neurodevelopment disorder, where a baby is born with an unusually small head due to abnormal brain development in the womb or after birth.  Complications of this disorder include seizures and developmental issues. Complete Report @  http://dpiresearch.com/report-details.php?P_ID=92 Due to the serious nature of globa

Diabetes Insulin Pen Market is anticipated to surpass US$ 5 Billion across the top 5 European countries of the France, Germany, Italy, Spain and United Kingdom by 2022. Long–term Growth Projection and Development:   Prefilled(Disposable) insulin pen grasps the dominant share in the top 5 European countries insulin pen market In 2016, there were over 7,800 Thousand users of insulin pen in the top 5 European countries Germany insulin pen market generated more than US$ 1.5 Billion in 2016 Spain has shown its potential to become leading #2 market with around 20% market share in 2016 Complete Report @  http://www.dpiresearch.com/report-details.php?P_ID=112 Market growth can be attributed to factors such as increasing number of patients with diabetes, high adoption rate, user–friendly design, surging popularity amid consumers, help avoid over/under–dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the f

China Potential Non–Invasive Prenatal Testing (NIPT) market is likely to reach more than US$ 1.7 Billion by 2024. Long–term Growth Projection and Development: • It is predicted that China Actual NIPT test volume will increase to 1.6 Million by 2024 • More than 3,00,000 NIFTY tests done in 2016 • Berry Genomics completes US$ 648 Million reverse merger in Shenzhen • Two–Child policy is likely to boost China NIPT market Growth in China NIPT market can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of China NIPT market. Due to expanding patient access to NIPT test, the China NIPT test market is poised to have a positive outlook in the year ahead. Complete Report @  http://www.dpiresearch.com/report-details.php?P_